Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma

Last Updated: Friday, May 19, 2023

This review article discusses safety of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel, all of which are approved CD19-directed CAR T-cell therapies for patients with relapsed/refractory large B-cell lymphoma. Common adverse events such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are discussed, as are hemophagocytic lymphohistiocytosis and other events.

Expert Opinion on Drug Safety

Cure

Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients With Multiple Myeloma

Transplantation and Cellular Therapy

ASTCT, CIBMTR, and ESBMT Clinical Practice Recommendations for Transplantation and Cellular Therapies

Journal of Blood Medicine

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma

Biology of Blood and Marrow Transplantation

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic

Expert Review of Anti-Infective Therapy

CAR-T Cell Therapy and Infection: A Review

Blood Advances

Comparison of 2-Year Outcomes With CAR T Cells (ZUMA-1) Versus Salvage Chemotherapy in Refractory Large B-Cell Lymphoma

The ASCO Post

Early-Phase Study Explores CAR T-Cell Therapy for Relapsed or Refractory B-Cell Lymphoma

Nature Reviews Clinical Oncology

Engineering Strategies to Overcome the Current Roadblocks in CAR T Cell Therapy

Journal of Clinical Oncology

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Journal of the Advanced Practitioner in Oncology

CAR T-Cell Therapy: Adverse Events and Management

CAR T-Cell Therapy Resource Center